[go: up one dir, main page]

MX2019000059A - Inhibidores de complementos y usos de los mismos. - Google Patents

Inhibidores de complementos y usos de los mismos.

Info

Publication number
MX2019000059A
MX2019000059A MX2019000059A MX2019000059A MX2019000059A MX 2019000059 A MX2019000059 A MX 2019000059A MX 2019000059 A MX2019000059 A MX 2019000059A MX 2019000059 A MX2019000059 A MX 2019000059A MX 2019000059 A MX2019000059 A MX 2019000059A
Authority
MX
Mexico
Prior art keywords
domain
polypeptide
vector
present
relates
Prior art date
Application number
MX2019000059A
Other languages
English (en)
Inventor
Christoph Schmidt
Hubert Schrezenmeier
Markus Anliker
Britta Höchsmann
Original Assignee
Univ Ulm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ulm filed Critical Univ Ulm
Publication of MX2019000059A publication Critical patent/MX2019000059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invención se refiere a un polipéptido multi-dominio que comprende (i) un primer dominio que comprende repetición de proteína de control de complementos (CCP) que es un dominio de aceleración de descomposición de convertasa para convertasas de las rutas clásica y alternativa de la activación de complementos, (ii) un dominio de reconocimiento de células huésped, y (iii) un segundo dominio que comprende CCP con la actividad del cofactor. La presente invención además se refiere a un polinucleótido que codifica dicho polipéptido multi-dominio, a un vector que comprende dicho polinucleótido, y a una célula huésped que comprende dicho polinucleótido y/o dicho vector. Además, la presente invención se refiere al polipéptido multi-dominio, el polipéptido, y el vector para uso en medicina y para el tratamiento y/o prevención de la activación inapropiada de complementos y/o una enfermedad que tiene activación de complemento inapropiado como un síntoma. Además, la presente invención se refiere a métodos y usos relacionados con polipéptido multi-dominio, el polipéptido, y el vector.
MX2019000059A 2016-06-28 2017-06-28 Inhibidores de complementos y usos de los mismos. MX2019000059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16176739 2016-06-28
PCT/EP2017/065979 WO2018002131A1 (en) 2016-06-28 2017-06-28 Complement inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2019000059A true MX2019000059A (es) 2020-09-07

Family

ID=56360183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000059A MX2019000059A (es) 2016-06-28 2017-06-28 Inhibidores de complementos y usos de los mismos.

Country Status (13)

Country Link
US (1) US12312387B2 (es)
EP (1) EP3474883B1 (es)
JP (1) JP7068203B2 (es)
KR (1) KR102566634B1 (es)
CN (1) CN109689084A (es)
AU (1) AU2017289214B2 (es)
CA (1) CA3029106A1 (es)
DK (1) DK3474883T3 (es)
ES (1) ES2925466T3 (es)
IL (1) IL263949A (es)
MX (1) MX2019000059A (es)
PL (1) PL3474883T3 (es)
WO (1) WO2018002131A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
JP2022508942A (ja) * 2018-10-22 2022-01-19 アイセルキーレクス セラピューティクス エルエルシー 変異ワクシニア・ウイルスおよびその使用
KR20220057530A (ko) * 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
EP4165181A2 (en) 2020-06-14 2023-04-19 Vertex Pharmaceuticals Incorporated Complement factor i-related compositions and methods
GB202203627D0 (en) 2022-03-16 2022-04-27 Univ Manchester Agents for treating complement-related disorders
KR20250004744A (ko) * 2022-04-11 2025-01-08 롱바이오 파마 (수조우) 컴퍼니 리미티드 보체-억제 하이브리드 단백질
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白
EP4525934A1 (en) 2023-01-05 2025-03-26 Complement Therapeutics Limited Agents and methods for treating complement diseases
WO2024234244A1 (zh) * 2023-05-15 2024-11-21 天辰生物医药(苏州)有限公司 偏向性补体抑制杂合蛋白
WO2025109172A1 (en) * 2023-11-24 2025-05-30 Universität Ulm Complement modulator
EP4559472A1 (en) * 2023-11-24 2025-05-28 Universität Ulm Complement modulator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0512733A2 (en) * 1991-05-03 1992-11-11 Washington University Modified complement system regulator
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
WO2010034015A2 (en) * 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
US9540626B2 (en) * 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof

Also Published As

Publication number Publication date
JP2019523238A (ja) 2019-08-22
ES2925466T3 (es) 2022-10-18
KR20190039090A (ko) 2019-04-10
CN109689084A (zh) 2019-04-26
PL3474883T3 (pl) 2022-09-19
EP3474883A1 (en) 2019-05-01
JP7068203B2 (ja) 2022-05-16
IL263949A (en) 2019-01-31
US20190202878A1 (en) 2019-07-04
WO2018002131A1 (en) 2018-01-04
EP3474883B1 (en) 2022-05-25
US12312387B2 (en) 2025-05-27
AU2017289214A1 (en) 2019-01-24
AU2017289214B2 (en) 2021-11-18
DK3474883T3 (da) 2022-08-29
KR102566634B1 (ko) 2023-08-14
CA3029106A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
MX2019000059A (es) Inhibidores de complementos y usos de los mismos.
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
PH12018500902A1 (en) Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MX2019007649A (es) Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
PH12018500477A1 (en) Recombinant vectors comprising 2a peptide
EP4253412A3 (en) Inhibition of cytokine-induced sh2 protein in nk cells
HK1245287A1 (zh) IL13RAα2結合劑和其在癌症治療中的用途
PH12014501604A1 (en) Polypeptides binding to human complement c5
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
CA3034771C (en) Immunotherapy markers and uses therefor
PH12016502433A1 (en) Modulation of nitrate content in plants
GT201700224A (es) Proteína de unión a rgma y su uso
EA201391005A1 (ru) Слитый белок против злокачественной опухоли
WO2019018841A3 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION OF COMBINATORIAL IMMUNO-ONCOLOGIC THERAPEUTIC AGENTS
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
AR101811A1 (es) Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular
MX388883B (es) Mutaciones en proteinas del grupo hierro-azufre que mejoran la utilizacion de xilosa.
EA201391546A1 (ru) Противораковый слитый белок
AR103586A1 (es) Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas
AR101146A1 (es) Proteína con actividad xilanasa
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
UY37041A (es) Composición para el control de plagas acuáticas
PH12017502345A1 (en) Novel thrombin inhibitors
BR112018001542A2 (pt) indutor da imunidade, polipeptídeo possuindo uma atividade indutora da imunidade, célula apresentadora de antígeno isolada e célula t isolada